The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice

Rimonabant was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was withdrawn from market due to the notably increased rates of psychiatric side effects. We have evaluated TM38837, a novel, largely peripherally...

Descripción completa

Detalles Bibliográficos
Autores principales: Micale, Vincenzo, Drago, Filippo, Noerregaard, Pia K., Elling, Christian E., Wotjak, Carsten T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435594/
https://www.ncbi.nlm.nih.gov/pubmed/30949045
http://dx.doi.org/10.3389/fphar.2019.00207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435594/
https://www.ncbi.nlm.nih.gov/pubmed/30949045
http://dx.doi.org/10.3389/fphar.2019.00207

Ejemplares similares